MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
MRI as outcome measure in facioscapulohumeral muscular dystrophy : 1-year follow-up of 45 patients. / Andersen, Grete; Dahlqvist, Julia R; Vissing, Christoffer R; Heje, Karen; Thomsen, Carsten; Vissing, John.
I: Journal of Neurology, Bind 264, Nr. 3, 2017, s. 438-447.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - MRI as outcome measure in facioscapulohumeral muscular dystrophy
T2 - 1-year follow-up of 45 patients
AU - Andersen, Grete
AU - Dahlqvist, Julia R
AU - Vissing, Christoffer R
AU - Heje, Karen
AU - Thomsen, Carsten
AU - Vissing, John
PY - 2017
Y1 - 2017
N2 - There is no effective treatment available for facioscapulohumeral muscular dystrophy type 1 (FSHD1), but emerging therapies are under way that call for a better understanding of natural history in this condition. In this prospective, longitudinal study, we used quantitative MRI to assess yearly disease progression in patients with FSHD1. Ambulatory patients with confirmed diagnosis of FSHD1 (25/20 men/women, age 20-75 years, FSHD score: 0-12) were tested with 359-560-day interval between tests. Using the MRI Dixon technique, muscle fat replacement was evaluated in paraspinal, thigh, and calf muscles. Changes were compared with those in FSHD score, muscle strength (hand-held dynamometry), 6-minute-walk-distance, 14-step-stair-test, and 5-time-sit-to-stand-test. Composite absolute fat fraction of all assessed muscles increased by 0.036 (CI 0.026-0.046, P < 0.001), with increases in all measured muscle groups. The clinical severity FSHD score worsened (10%, P < 0.05), muscle strength decreased over the hip (8%), neck (8%), and back (17%) (P < 0.05), but other strength measures, 6-minute-walk-distance, 5-times-sit-to-stand-test, and 14-step-stair-test were unchanged. Changes in muscle strength, FSHD score, and fat fraction did not correlate. This first study to systemically monitor quantitative fat replacement longitudinally in FSHD1 shows that MRI provides an objective measure of disease progression, often before changes can be appreciated in strength and functional tests. The study indicates that quantitative MRI can be a helpful end-point in follow-up and therapeutic trials of patients with FSHD1.
AB - There is no effective treatment available for facioscapulohumeral muscular dystrophy type 1 (FSHD1), but emerging therapies are under way that call for a better understanding of natural history in this condition. In this prospective, longitudinal study, we used quantitative MRI to assess yearly disease progression in patients with FSHD1. Ambulatory patients with confirmed diagnosis of FSHD1 (25/20 men/women, age 20-75 years, FSHD score: 0-12) were tested with 359-560-day interval between tests. Using the MRI Dixon technique, muscle fat replacement was evaluated in paraspinal, thigh, and calf muscles. Changes were compared with those in FSHD score, muscle strength (hand-held dynamometry), 6-minute-walk-distance, 14-step-stair-test, and 5-time-sit-to-stand-test. Composite absolute fat fraction of all assessed muscles increased by 0.036 (CI 0.026-0.046, P < 0.001), with increases in all measured muscle groups. The clinical severity FSHD score worsened (10%, P < 0.05), muscle strength decreased over the hip (8%), neck (8%), and back (17%) (P < 0.05), but other strength measures, 6-minute-walk-distance, 5-times-sit-to-stand-test, and 14-step-stair-test were unchanged. Changes in muscle strength, FSHD score, and fat fraction did not correlate. This first study to systemically monitor quantitative fat replacement longitudinally in FSHD1 shows that MRI provides an objective measure of disease progression, often before changes can be appreciated in strength and functional tests. The study indicates that quantitative MRI can be a helpful end-point in follow-up and therapeutic trials of patients with FSHD1.
KW - Adipose Tissue
KW - Adult
KW - Aged
KW - Clinical Trials as Topic
KW - Disease Progression
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Image Interpretation, Computer-Assisted/methods
KW - Longitudinal Studies
KW - Magnetic Resonance Imaging/methods
KW - Male
KW - Middle Aged
KW - Muscle Strength
KW - Muscle, Skeletal/diagnostic imaging
KW - Muscular Dystrophy, Facioscapulohumeral/diagnostic imaging
KW - Outcome Assessment (Health Care)/methods
KW - Prospective Studies
KW - Severity of Illness Index
KW - Young Adult
U2 - 10.1007/s00415-016-8361-3
DO - 10.1007/s00415-016-8361-3
M3 - Journal article
C2 - 28000006
VL - 264
SP - 438
EP - 447
JO - Deutsche Zeitschrift fur Nervenheilkunde
JF - Deutsche Zeitschrift fur Nervenheilkunde
SN - 0939-1517
IS - 3
ER -
ID: 194029732